Updates are available Correction dated 2021-11-12
Click to view Correction: https://doi.org/10.1038/s41409-021-01524-2
-
Authors
Schetelig, Johannes https://orcid.org/0000-0002-2780-2981
Hoek, Jennifer
Stilgenbauer, Stephan
Middeke, Jan Moritz https://orcid.org/0000-0003-3250-293X
Andersen, Niels Smedegaard
Fox, Christopher P. https://orcid.org/0000-0002-6322-9254
Lenhoff, Stig
Volin, Liisa
Shimoni, Avichai
Schroyens, Wilfried
van Gelder, Michel
Bunjes, Donald
van Biezen, Anja
Baldauf, Henning
de Wreede, Liesbeth C.
Tournilhac, Olivier
Kröger, Nicolaus https://orcid.org/0000-0002-2961-4183
Yakoub-Agha, Ibrahim
Dreger, Peter https://orcid.org/0000-0002-7429-8570
- License Information
-
More Information
Article History
Received: 17 December 2019
Accepted: 24 July 2020
First Online: 16 August 2020
Change Date: 12 November 2021
Change Type: Correction
Change Details: A Correction to this paper has been published:
Change Details: https://doi.org/10.1038/s41409-021-01524-2
Compliance with ethical standards
:
: JS—consultancy honoraria from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Molmed; lecture fees from AstraZeneca, Janssen, Roche, Gilead, Abbvie, Sanofi, Novartis; research support from Genzyme, Sanofi, GSK, Novartis, Abbvie. CPF—Speaker/consultancy honoraria and travel support from Janssen. SS—Honoraria for consultancy, Advisory board member, Speaker honoraria, Research grants, Travel support from AbbVie, Amgen, AstraZeneca, Celgene, Gilead, GSK, Hoffmann La-Roche, Janssen, Novartis. PD—consultancy for AbbVie, AstraZeneca, Gilead, Janssen, Novartis, Riemser, Roche; speakers bureau for AbbVie, Gilead, Novartis, Riemser, Roche; research support from Neovii and Riemser. The remaining authors declared no conflict of interest.
